lapaquistat cholesterollowering drug candidate abandoned marketed unlike statins inhibit hmgcoa reductase lapaquistat metabolites inhibit squalene synthase downstream synthesis cholesterol hoped side effects reduced disturbing mevalonate pathway important biochemical molecules besides cholesterol however increasing evidence statins inhibit mevalonate pathway may clinically useful affect molecules including protein march takeda halted development effective lowering lowdensity lipoprotein cholesterol dosedependent manner development drug ceased due observations clinical trials might cause liver damage high dose trial data knockout mouse studies suggests accumulation high levels metabolic substrate squalene synthase derivatives thereof account liver toxicity squalene synthase efforts mitigate substrate accumulation would likely necessary clinical success squalene synthase inhibitor drug article relating cardiovascular system stub help wikipedia expanding httpsenwikipediaorgwikilapaquistat